Zacks Investment Research upgraded shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) from a hold rating to a buy rating in a research report sent to investors on Tuesday, June 13th. The firm currently has $9.00 target price on the stock.
According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
Other analysts have also recently issued research reports about the stock. Cowen and Company started coverage on shares of Neos Therapeutics in a research note on Wednesday, April 5th. They issued an outperform rating and a $20.00 price target on the stock. BMO Capital Markets reiterated an outperform rating and issued a $15.00 price target on shares of Neos Therapeutics in a research note on Saturday, March 11th. Finally, ValuEngine upgraded shares of Neos Therapeutics from a strong sell rating to a sell rating in a research note on Thursday, May 18th.
Neos Therapeutics (NEOS) traded up 2.92% during midday trading on Tuesday, hitting $7.05. The company’s stock had a trading volume of 756,964 shares. The firm’s market cap is $159.05 million. Neos Therapeutics has a 12 month low of $4.85 and a 12 month high of $9.99. The company’s 50 day moving average price is $7.92 and its 200 day moving average price is $6.84.
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.07. The business had revenue of $5.63 million for the quarter. Neos Therapeutics had a negative net margin of 719.86% and a negative return on equity of 512.10%. Analysts expect that Neos Therapeutics will post ($3.24) EPS for the current year.
WARNING: “Neos Therapeutics, Inc. (NEOS) Rating Increased to Buy at Zacks Investment Research” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/07/14/neos-therapeutics-inc-neos-rating-increased-to-buy-at-zacks-investment-research.html.
Hedge funds have recently bought and sold shares of the company. Mission Wealth Management LLC acquired a new stake in Neos Therapeutics during the first quarter worth $122,000. Teachers Advisors LLC increased its stake in Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock worth $149,000 after buying an additional 3,572 shares during the period. Sheaff Brock Investment Advisors LLC acquired a new stake in Neos Therapeutics during the first quarter worth $216,000. Wells Fargo & Company MN increased its stake in Neos Therapeutics by 130.3% in the first quarter. Wells Fargo & Company MN now owns 48,030 shares of the company’s stock worth $346,000 after buying an additional 27,174 shares during the period. Finally, Hunter Associates Investment Management LLC acquired a new stake in Neos Therapeutics during the first quarter worth $360,000. Hedge funds and other institutional investors own 33.11% of the company’s stock.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.